Archive for October, 2010

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD

HUDDINGE, Sweden, November 1, 2010 /PRNewswire/ -- Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®

SEATTLE, Nov. 1, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for Pixuvri® (pixantrone dimaleate) as monotherapy for the treatment of...

March of Dimes Honors the Half a Million Infants Born too Soon During Prematurity Awareness Month

WHITE PLAINS, N.Y., Nov. 1, 2010 /PRNewswire-USNewswire/ -- More than half a million babies are born too soon each year and thousands don't live to celebrate their first birthday as a result.   November is Prematurity Awareness Month, and people can learn more about the seriousness of...

En el Mes de la Concientización sobre la Prematuridad, March of Dimes rinde homenaje al medio millón de bebés que nacieron prematuramente en el último año

WHITE PLAINS, Nueva York, 1 de noviembre de 2010 /PRNewswire-HISPANIC PR WIRE/ -- Más de medio millón de bebés nacen cada año en forma prematura y, como resultado de ello, son miles los que no llegan a vivir lo suficiente como para celebrar su primer año.   Noviembre...

Hope for the Journey – Diabetes Research at VA

WASHINGTON, Nov. 1 /PRNewswire/ -- Group visits, telemedicine, peer counseling, and Internet-based education and case management are among the innovative strategies Department of Veterans Affairs (VA) researchers are studying to increase access to care and improve the health outcomes of Veterans...

Track Down Awarepoint at AMSUS 116th Annual Meeting

SAN DIEGO, Oct. 31 /PRNewswire/ -- WHO: Awarepoint, a provider of ZigBee-based real-time location solutions (RTLS) for hospitals, will exhibit in Booth #215 during AMSUS, the Society of the Federal Health Agencies. WHAT: Stop by and meet with Vice Admiral Harold Koenig, M.D. (retired) along with...

Philips Introduces High Field Open MRI for Radiation Oncology

ANDOVER, Mass., Oct. 31 /PRNewswire/ -- Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the Philips Panorama High Field Open (HFO) Oncology Configuration for radiation therapy, a magnetic resonance (MR) imaging solution for dedicated oncology use, at this year's American Society...

CyberKnife Radiosurgery for Early-Stage Breast Cancer

SUNNYVALE, Calif., Oct. 31 /PRNewswire/ -- Accuray Incorporated, (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment. These two studies, from the University...

Testosterone In Young Type 2 Diabetics To Be Studied

An endocrinologist in the University at Buffalo's School of Medicine and Biomedical Sciences has received a three-year $400,000 Junior Faculty Award from the American Diabetes Society to study the effects of low testosterone levels in young men with type 2...

VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis

NEW YORK, Oct. 30 /PRNewswire/ -- See video from Novartis at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=193bd015-3567-4799-8ee7-81dfac6c6369 Novartis announced that the US Food and Drug Administration (FDA) has approved Afinitor®; (everolimus) tablets for patients with...
Get Adobe Flash playerPlugin by wpburn.com wordpress themes